Vistra CEO Jim Burke just invested roughly $1.17 million in VST near $135. With AI data centers devouring electricity, nuclear agreements with Meta and AWS, surging EBITDA and a seemingly irresistible 0.34 PEG, the bull case looks powerful. But prior insider selling and enormous growth expectations make the valuation considerably more complicated.

Read entire article

ITT CEO Luca Savi just bought approximately $1 million of stock after previously selling more than $23 million. Meanwhile, the $4.8 billion SPX FLOW acquisition is transforming ITT, organic revenue grew nearly 13%, and guidance is rising—but at roughly 25x forward earnings, investors are already paying for plenty of success. We dig into the insider signal, fundamentals, valuation, institutional ownership and risks.

Read entire article

Klarna has fallen roughly 75% from its post-IPO high, yet revenue rose 27%, transaction margin dollars surged 42%, and co-founder/CEO Sebastian Siemiatkowski just bought $9.95 million of KLAR. Is Wall Street pricing a broken fintech—or overlooking a rapidly evolving payments platform?

Read entire article

DICK’S Sporting Goods plunged roughly 30% as Foot Locker weakness rattled Wall Street. Then three directors bought $2.94 million. With core DICK’S comps up 4.9%, operating cash flow at $792 million and the stock at 9.3x forward earnings, is Wall Street pricing temporary integration pain like permanent deterioration?

Read entire article

NGL Energy Partners director John Raymond just put $5.1 million behind the turnaround. With record Permian water volumes, rising EBITDA and heavy institutional ownership, NGL looks increasingly compelling—but leverage keeps our FunStock Index at 7.95/10.

Read entire article

Kura Oncology is evolving from a clinical-stage biotech into a commercial oncology company. With KOMZIFTI gaining traction, over $500 million in cash, strong institutional ownership and multiple Phase 3 catalysts ahead, is KURA becoming one of biotech's most compelling long-term opportunities?

Read entire article

Medifast (NYSE: MED) has nearly $170 million in cash, no debt, insider buying and a bold strategic pivot through Trilivy. But shrinking revenues and GLP-1 competition still cast a long shadow. Here's the complete bull vs. bear case.

Read entire article

SiteOne Landscape Supply isn't flashy—but it may be one of the market's most overlooked industrial compounders. After a sharp correction, CEO Doug Black invested more than $816,000 of his own money while institutions continue to dominate the shareholder base. We examine the valuation, competitive moat, earnings, risks, and whether this roll-up story deserves another look.

Read entire article

Bunge isn't merely a grain trader—it's one of the world's most important agricultural infrastructure companies. After a 43% rally from our 2025 recommendation, a healthy pullback, another insider purchase, stronger earnings guidance and accelerating Viterra synergies make the long-term investment story compelling once again.

Read entire article

Huntsman isn't simply a cyclical chemical company anymore. Between repeated insider buying, a transformational $12.5 billion merger with Olin, trading at just 0.64x book value and more than $400 million in projected synergies, investors may be looking at one of the market's more intriguing industrial turnaround opportunities.

Read entire article